MyMD Pharmaceuticals files 8-K/A to correct terms of ~$13.9M private placement of preferred stock and warrants

Q/C TECHNOLOGIES, INC.

Corrected typographical errors in terms of Series G and Series F-1 Preferred Stock and Warrants from May 20, 2024 private placements.
Private placements expected to raise approx. $13.9M gross ($8.9M Series G, $5.0M Series F-1).
Preferred stock convertible at $1.816/share, with 10% annual dividend; redemption beginning Dec 2024.
Company must hold stockholder meeting by Aug 1, 2024 to seek approval for share issuance above 19.99% and increase authorized shares.
Net proceeds to be used for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.